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INTERFERON LAMBDA MEETING
Meeting Overview: Interferon Lambda—Disease Impact
and Therapeutic Potential
Thomas R. O’Brien,1 Howard A. Young,2 Raymond P. Donnelly,3 and Ludmila Prokunina-Olsson4
A meeting entitled, ‘‘Interferon Lambda: Disease Impact and Translational Potential,’’ was held on the
campus of the National Institutes of Health in Bethesda, Maryland, on October 25–26, 2018. To our
knowledge, this was the first meeting that focused exclusively on interferon lambda (IFN-l). The meeting’s
purpose was to enhance interdisciplinary communication and promote new collaborations. The gathering
brought together an international group of scientists from a wide range of disciplines. Sessions included: IFN-
l Biology, Therapy and Genetic Variation; IFN-l and Hepatitis C Virus Infection; IFN-l in Other Infections;
and IFN-l—Hepatic Fibrosis and Cancer. The next meeting on IFN-l is planned for 2020.
Keywords: cancer, genetics, hepatitis C virus, immunology, infectious diseases, interferon lambda
Background
On October 25–26, 2018 a meeting entitled, ‘‘IFN-l:Disease Impact and Translational Potential,’’ was held
on the campus of the National Institutes of Health in Be-
thesda, Maryland. To our knowledge, this was the first ever
meeting to focus exclusively on IFN-l. The meeting’s
purpose was to enhance interdisciplinary communication
and promote new collaborations in research on IFN-l, a
rapidly developing field with tremendous translational po-
tential for cancer, infectious diseases, and immunology.
Discovery of interferon lambda 1–3
and development of interferon lambda-based
therapy
The interferon lambda (IFN-l) family was discov-
ered relatively recently (Kotenko and others 2003; Sheppard
and others 2003; Prokunina-Olsson and others 2013), and
knowledge of the functional range and mechanisms of
these cytokines is still emerging. In 2003, 2 groups inde-
pendently reported the discovery of IFN-l1–3, as well as
their cognate receptors (Kotenko and others 2003; Sheppard
and others 2003). Those investigators demonstrated that IFN-
ls (also known at type III IFNs) have striking similarities to
type I IFNs (IFN-a/b) in that they induce expression of a host
of antiviral and antiproliferative genes by signaling through
the JAK/STAT pathway. The lambda receptor (IFN-lR1)
was found to be more restricted in expression than re-
ceptors for type I IFNs, an observation that led to the
development of pegylated-IFN-l as a potentially better
tolerated alternative to IFN-a drug products as a treatment
for certain viral infections. Clinical trials for treatment of
hepatitis B virus (HBV) and hepatitis C virus (HCV) in-
fections were initiated. The clinical results from these
trials demonstrated that pegylated-IFN-l had a superior
safety profile compared with pegylated-IFN-a, (Muir and
others 2010, 2014; Chan and others 2016); however, it was
deemed less effective than alternative treatments for these
infections. Nonetheless, because of that developmental
work, pegylated-IFN-l is ready for deployment if new
indications are identified.
Genetic studies and discovery of IFNL4
In 2009, genome-wide association studies (GWAS)
demonstrated strong associations between single nucleotide
polymorphisms (SNPs) in the IFN-l chromosomal region
and HCV clearance (Ge and others 2009; O’Brien 2009;
Suppiah and others 2009; Tanaka and others 2009). Because
of those findings, genotype for the rs12979860 SNP (com-
monly referred to as ‘‘IL28B’’) was developed as a clinical
test to predict response to pegylated-IFN-a-based treatment
of HCV. In 2013, the discovery of the fourth IFN-l gene
(IFNL4), the IFN-l4 protein, and the IFNL4-DG/TT genetic
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Table 1. Meeting Program—‘‘IFN-l: Disease Impact and Translational Potential,’’ National Institutes
of Health, Bethesda, Maryland, October 25–26, 2018
Thursday, October 25, 2018
Session 1: IFN-l Biology, Therapy and Genetic Variation
Moderators: Howard Young, Rune Hartmann
0910: An Overview of the IFN-k Proteins and Their Biological Functions—Raymond Donnelly, Center for Drug Evaluation
and Research, Food and Drug Administration, USA
0935: Trials of IFN-k1 in Chronic Hepatitis Virus Infections—Jeffrey Glenn, Department of Gastroenterology, Stanford
University School of Medicine, USA
1000: Structure and Engineering of an IFN-k Receptor Complex Provides a Blueprint for Developing the Next Generation
IFN-k Therapeutics—Juan Mendoza, Department of Molecular and Cellular Physiology, Stanford University School of
Medicine, USA
1045: IFNL4 Discovery and Genetics—Ludmila Prokunina-Olsson, Division of Cancer Epidemiology and Genetics,
National Cancer Institute, USA
1110: Selected Talk—A Polymorphic Residue That Attenuates the Antiviral Potential of Interferon Lambda 4 in Hominid
Lineages—Connor Bamford, MRC-University of Glasgow Centre for Virus Research, UK
Session 2: IFN-l and HCV Infection
Moderators: Barbara Rehermann, Jacob George
1135: What Have We Learned from Studies of IFN-k Variants and HCV?—Thomas O’Brien, Division of Cancer
Epidemiology and Genetics, National Cancer Institute, USA
1200: Broad Impact of Interferon Lambda 4 on Hepatitis C Virus Diversity—Vincent Pedergnana, Human Genetics,
Genome Institute of Singapore
1400: How does IFN-k impair HCV clearance? Presentations/panel discussion:
Do Genetic Polymorphisms within the IFNL4 Gene Influence the Transcription of the IFNL3 Gene?—Rune Hartmann,
Department of Molecular Biology and Genetics, Aarhus University, Denmark
Interferon Lambda 4 Accumulates in the Endoplasmatic Reticulum and Causes ER Stress—Markus Heim, Department of
Biomedicine, University of Basel, Switzerland
Collaborative Roles of Type I and III Interferons in Viral Restriction—Ram Savan, Department of Immunology, University
of Washington, USA
Session 3: IFN-l—Hepatic Fibrosis and Cancer
Moderators: Thomas O’Brien, Ludmila Prokunina—Olsson
1540: Association of IFN-k Variants with Viral and Non-Viral Hepatic Fibrosis—Jacob George, Storr Liver Centre,
Westmead Institute for Medical Research/University of Sydney School of Medicine, Australia
1605: IFNL3/IFNL4 Locus Genotype is Associated with HCV+ Liver Cancer and Enrichment of Mutations in the WNT
Signaling Pathway—Olusegun Onabajo, Division of Cancer Epidemiology and Genetics, NCI, USA
1630: A Genetic Variant Near IFNL3 Associates with Mucinous Ovarian Carcinoma—Linda Kelemen, Department of
Public Health Sciences, The Medical University of South Carolina, USA
1655: IFNL4 in Prostate Cancer: Association with Sexually Transmitted Infections, Survival and Interferon Signature in
Tumors—Tsion Minas, Center for Cancer Research, National Cancer Institute, USA
Friday, October 26, 2018
Session 4: IFN-l in Other Infections
Moderators: Kim Green, Eric Meissner, Raymond Donnelly
0900: Type III IFN Signaling in Placental Antiviral Defenses—Carolyn Coyne, University of Pittsburgh School of
Medicine, USA
0925: IFN-k and Viral Invasion Across Anatomic Barriers—Helen Lazear, Department of Microbiology and Immunology,
UNC School of Medicine, USA
0950: IFN-k and Bacterial Infections—Jonathan Kagan, Harvard Medical School, USA
1035: Regulation of Persistent Murine Norovirus Infection by the Microbiota and IFN-k—Megan Baldridge, Washington
University School of Medicine, USA
1100: Selected Talk—Type III Interferons Regulate Intestinal Inflammation—Ivan Zanoni, Harvard Medical School, USA
1115: IFN-k in Gastrointestinal Infections and Homeostasis—Sergei Kotenko, New Jersey Medical School, USA
1230: IFN-ks Fine-Tune Front Line Antiviral Immunity Against Influenza Virus Infection for Optimal Protection and
Minimal Host Damage—Evangelos Andreakos, Center for Clinical and Translational Research, Biomedical Research
Foundation, Academy of Athens, Greece
1255: IFN-k Enhances Adaptive Antiviral Immunity by Boosting TSLP Release Upon Mucosal Immunization—Peter
Staeheli, Institute of Virology, Department for Medical Microbiology and Hygiene, University of Freiburg, Germany
1320: Selected Talk—IFN-k Directs Migratory Dendritic Cell Function to Orchestrate T Cell Immunity During Influenza
Virus Infection—Emily Hemann, University of Washington, USA
1345: Bonus Session—Roundtable Discussion on Extramural Funding
Moderators: Danielle Carrick (NCI) and Rudy Alarcon (NIAID)






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































polymorphism were reported (Prokunina-Olsson and others
2013). IFNL4-DG/TT is a common ‘‘knockout’’ variant that
controls generation of IFN-l4 protein. This polymorphism
is one of the most highly selected variants in the human
genome, with marked differences in allele frequency be-
tween racial groups (Prokunina-Olsson and others 2013;
Key and others 2014). The rs12979860 SNP lies in intron 1
of IFNL4 and is in strong linkage disequilibrium with
IFNL4-DG/TT. IFNL4-DG/TT is the primary functional
variant for spontaneous clearance of HCV and response to
HCV treatment with IFN-a and ribavirin, (Prokunina-Olsson
and others 2013; Aka and others 2014; O’Brien and others
2015) as the protein generating variant is deleterious for
clearance of HCV. The mechanism underlying this paradox-
ical association is not completely clear; however, IFN-l4 at-
tenuates antiviral responses at least in part by enhancing
negative regulation of IFN signaling (Obajemu and others
2017). New direct acting antiviral agents have revolution-
ized the treatment of chronic hepatitis C, and IFNL4 geno-
type also predicts response to those regimens (Meissner and
others 2014; O’Brien and others 2017a, 2017b).
Other diseases and conditions have been linked to IFN-k
genotypes. Hepatic fibrosis is a key factor in the pathway
to liver cancer. Genotype for IFNL4-DG/TT or IFNL4
rs12979860 predicts the rate of development of hepatic
fibrosis and cirrhosis not only in HCV-infected patients
but also in the settings of HBV infection or nonalcoholic fatty
liver disease (Eslam and others 2015; Petta and others 2017).
A GWAS for mucinous ovarian carcinoma, a rare cancer
subtype that can be difficult to distinguish from metastatic
carcinomas to the ovary, reported an association for a marker
strongly linked with IFNL4 genotype (Kelemen and others
2015). For both fibrosis and mucinous ovarian carcinoma, the
IFN-l4 protein generating IFNL4 allele had a relatively
strong protective association. The IFNL4-DG allele was also
associated with the risk of aggressive prostate cancer in in-
dividuals at risk of sexually transmitted infections, presum-
ably due to impaired clearance of some viral infections due to
the presence of IFN-l4 (Minas and others 2018). Further-
more, the IFNL4-DG allele associates with an IFN-related
DNA damage resistance signature in prostate tumors, which
may affect response to cancer immunotherapies; overall
survival of prostate cancer patients was also reduced in car-
riers of this allele (Tang and others 2018).
IFN-ks protect against a range of infections
Recent studies demonstrated that IFN-l plays an impor-
tant role in a broad range of infections. Using murine
models, investigators demonstrated that IFN-l can act at
tissue barriers to provide frontline immunological protection
against neuroinvasive (West Nile virus), gastrointestinal
(norovirus), and respiratory (influenza) viral infections, as
well as at the placental barrier (Zika virus) (Baldridge and
others 2015; Lazear and others 2015a, 2015b; Nice and
others 2015; Bayer and others 2016; Galani and others
2017). Other studies have provided evidence that IFN-l
plays a role in bacterial and fungal infections (Espinosa and
others 2017; Odendall and others 2017; Schnepf and Stae-
heli 2017). However, as mice produce only IFN-l2 and IFN-
l3, the possible role of IFN-l4 in these infections could not
be addressed in those studies. However, strong evolutionary
selection against the IFNL4-DG allele (Key and others
2014) suggests IFN-l4 could impact infectious diseases
besides HCV.
The Meeting
This meeting brought together an international group of
scientists from a wide range of disciplines, including im-
munology, virology, human genetics, epidemiology, and
hepatology. The agenda included 20 invited talks and 3 oral
presentations that were selected from submitted abstracts
(Table 1). Sessions included: IFN-l Biology, Therapy and
Genetic Variation; IFN-l and HCV Infection; IFN-l in
Other Infections; and IFN-l—Hepatic Fibrosis and Cancer.
In addition, there was a lively poster session (Table 2) and a
roundtable discussion regarding potential NIH funding op-
portunities for research projects.
This special issue of the Journal of Interferon and Cy-
tokine Research includes articles by many of the scientists
who gave presentations during the meeting. It provides an
update to an earlier issue of JICR that focused on the bi-
ology and physiology of IFN-l, (Donnelly and Kotenko
2010) and reflects the considerable recent progress regard-
ing our knowledge of the IFN-l genes, their corresponding
proteins, and biological functions.
Future Meetings
As the meeting organizers, we were gratified by the
excellent presentations, collegial discussions, and overall
enthusiastic response to this meeting. Many attendees
suggested that this should be the first in an ongoing series
of meetings on IFN-l. We plan to hold the next meeting
in 2020.
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